Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 3
2003 5
2004 6
2005 6
2006 9
2007 9
2008 5
2009 8
2010 5
2011 3
2012 7
2013 3
2014 6
2015 6
2016 9
2017 6
2018 7
2019 14
2020 15
2021 21
2022 23
2023 17
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Results by year

Filters applied: . Clear all
Page 1
Case report: Cerebral sinus vein thrombosis in VEXAS syndrome.
Zisapel M, Seyman E, Molad J, Hallevi H, Mauda-Havakuk M, Jonas-Kimchi T, Elkayam O, Eviatar T. Zisapel M, et al. Among authors: elkayam o. Front Med (Lausanne). 2024 Apr 8;11:1377768. doi: 10.3389/fmed.2024.1377768. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38651063 Free PMC article.
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME, Nair P, Terrier B, Walz B, Bourdin A, Jayne DRW, Jackson DJ, Roufosse F, Börjesson Sjö L, Fan Y, Jison M, McCrae C, Necander S, Shavit A, Walton C, Merkel PA; MANDARA Study Group. Wechsler ME, et al. N Engl J Med. 2024 Mar 7;390(10):911-921. doi: 10.1056/NEJMoa2311155. Epub 2024 Feb 23. N Engl J Med. 2024. PMID: 38393328 Clinical Trial.
Tocilizumab Dose Tapering Based on a Model-Based Algorithm is Feasible in Clinical Practice: A Short Communication.
Hooijberg F, Layegh Z, Leeuw M, Boekel L, van den Berg SPH, Ruwaard J, Bastida C, Huitema ADR, Pel S, Elkayam O, de Vries A, Nurmohamed M, Rispens T, Dorlo TPC, Wolbink G. Hooijberg F, et al. Among authors: elkayam o. Ther Drug Monit. 2024 Jan 24. doi: 10.1097/FTD.0000000000001168. Online ahead of print. Ther Drug Monit. 2024. PMID: 38287880
Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study).
Aymon R, Mongin D, Bergstra SA, Choquette D, Codreanu C, De Cock D, Dreyer L, Elkayam O, Huschek D, Hyrich KL, Iannone F, Inanc N, Kearsley-Fleet L, Koca SS, Kvien TK, Leeb BF, Lukina G, Nordström DC, Pavelka K, Pombo-Suarez M, Rodrigues A, Rotar Z, Strangfeld A, Verschueren P, Westermann R, Zavada J, Courvoisier DS, Finckh A, Lauper K. Aymon R, et al. Among authors: elkayam o. Ann Rheum Dis. 2024 Mar 12;83(4):421-428. doi: 10.1136/ard-2023-224670. Ann Rheum Dis. 2024. PMID: 38071508 Free PMC article.
Effect of Secukinumab and Tumor Necrosis Factor Inhibitors on Humoral Response to BNT162b2 mRNA Vaccine in Patients With Spondyloarthritis Compared to Immunocompetent Controls.
Eviatar T, Furer V, Polachek A, Zisman D, Peleg H, Elalouf O, Levartovsky D, Kaufman I, Broyde A, Haddad A, Feld J, Aassi M, Quebe-Fehling E, Alarcon I, Pel S, Paran D, Elkayam O. Eviatar T, et al. Among authors: elkayam o. J Rheumatol. 2024 Apr 1;51(4):415-422. doi: 10.3899/jrheum.2023-0357. J Rheumatol. 2024. PMID: 37914221 Free article.
166 results